A Year In Review
The bispecific field is expanding fast, with 3,162 drugs now in development—a 32% increase from last year. In 2024, clinical momentum surged, with a record 608 new trials initiated, highlighting growing confidence in this space.
This report covers key approvals, emerging trial trends, regulatory updates, and investment shifts, giving you the insights needed to stay ahead.
Download Now
Discover the latest bispecific breakthroughs!
Part 1 of the Landscape Review covers key drug approvals, new therapeutic classes, and emerging scaffold formats, alongside insights into clinical trial growth, target selection, and late-stage development trends.
Part 1: The Drug & Trial Landscape
Part 2: The Commercial Landscape & Future Outlook
Part 3: The Full 2024 Landscape Review
Report Contents
The Drug Landscape
An overview of clinical entries, discontinuations, and top targets at each phase. Plus insights into new scaffold formats, and emerging therapeutic classes.
The Trial Landscape
A breakdown of 608 new bispecific trials, covering phase distribution, disease indications, and trial locations.
The Commercial Landscape
2024’s deal and company activity, with a spotlight on the top 10 highest-value deals and emerging industry players.
The Future of the Bispecific Space
A look ahead at 2025’s potential approvals and the number of trials set to conclude over the next decade, shaping the future of bispecific innovation.
Regulatory Updates
A summary of 2024’s regulatory updates by type, with a look at the top 5 drugs with the most regulatory activity.
You May Also Be Interested In...
Bispecific: 2024 Landscape Review
ADC: 2024 Landscape Review
T Cell Engagers: Revolutionizing Autoimmune Disease Treatment
Beacon Bispecific: SITC 2024 Post-Conference Report
Strategic Insights for Biopharma Innovation Report
H1 2024 Bispecific Landscape Review
Find Out More
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape. Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
